Share this Page:
In this paper, published in Current Treatment Options in Oncology last month, the authors review the recent randomised controlled clinical trials looking at the use of post-surgery (adjuvant) vascular endothelial growth factor (VEGF) inhibitors for the treatment of renal cell carcinoma (RCC) that has not spread. The authors recommend, based on current data, that adjuvant sunitinib should not be used routinely.
Further studies are needed to identify those patients who will most likely benefit from adjuvant treatment. The authors recommend participation in a clinical trial as the preferred treatment option for patients with high-risk, non-metastatic RCC who are planned for surgery.